Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
383 studies found for:    KRAS
Show Display Options
Rank Status Study
1 Recruiting Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Other: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
2 Completed KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009
Condition: Colorectal Carcinoma
Intervention:
3 Recruiting Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer
Condition: Colorectal Cancer Metastatic
Intervention: Genetic: KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
4 Active, not recruiting
Has Results
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Condition: Non Small Cell Lung Carcinoma
Interventions: Drug: AZD6244;   Drug: Erlotinib;   Drug: AZD6244 + Erlotinib
5 Recruiting Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Condition: Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Interventions: Drug: Sorafenib and irinotecan combination;   Drug: Sorafenib monotherapy;   Drug: Irinotecan monotherapy
6 Completed Epidemiologic Study of KRAS Mutation in Brazilian Patients With Advanced or Metastatic Non Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Intervention:
7 Not yet recruiting A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status
Condition: Colorectal Cancer
Interventions: Drug: Anti-EGFR-Containing Regimen;   Drug: Bevacizumab-containing regimen;   Drug: Chemotherapy
8 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
9 Completed KRAS Wild-type Metastatic Colorectal Cancer Trial
Condition: Colorectal Cancer
Interventions: Drug: Dacogen™ (decitabine);   Drug: Vectibix® (panitumumab)
10 Completed Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe
Condition: Metastatic Colorectal Cancer
Intervention: Other: Other
11 Completed Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis
Condition: Colorectal Cancer
Interventions: Other: Plasma Analysis of circulating cell free DNA;   Other: Tumor tissue analysis of circulating cell free DNA
12 Withdrawn Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases
Conditions: Colorectal Cancer Metastatic;   Liver Metastases;   KRAS Mutated Colorectal Cancer
Interventions: Drug: Modified FOLFOX6;   Biological: Aflibercept;   Procedure: Surgery
13 Active, not recruiting Comparison of AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients
Condition: Non Small Cell Lung Cancer
Interventions: Drug: AZD6244;   Drug: docetaxel;   Drug: Placebo
14 Completed Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine Patients
Condition: Colorectal Neoplasms
Intervention:
15 Withdrawn Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Intervention: Drug: capecitabine and cetuximab
16 Completed MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Mek Inhibitor MSC1936369B;   Drug: Placebo;   Drug: FOLFIRI
17 Completed Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab, erlotinib;   Drug: bevacizumab;   Drug: low dose capecitabine
18 Active, not recruiting RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab
Condition: Colorectal Cancer Metastatic
Intervention: Drug: FOLFIRI + Cetuximab
19 Completed A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
Conditions: KRAS Positive Patients With Non-small Cell Lung Cancer;   Squamous Cell Non-small Cell Lung Cancer
Intervention: Drug: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
20 Recruiting Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
Condition: Cancer
Intervention: Genetic: KRAS-variant

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years